<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520945</url>
  </required_header>
  <id_info>
    <org_study_id>Chondrogen</org_study_id>
    <nct_id>NCT04520945</nct_id>
  </id_info>
  <brief_title>Phase 2B Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis</brief_title>
  <official_title>Phase 2B: Randomized Double-Blinded Clinical Study of Chondrogen for Treatment of Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meluha Life Sciences SDN BHD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meluha Life Sciences SDN BHD</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary osteoarthritis is a debilitating disease characterized by extensive damage to the&#xD;
      joints and excruciating pain leading to loss of activity and depression. Despite advances in&#xD;
      diagnosis, the quest for the development of a disease-modifying osteoarthritis drug has&#xD;
      proven unsuccessful. Human cartilage only has limited regenerative potential. Transplantation&#xD;
      is a promising strategy given the high proliferative capacity of MSCs and their potential to&#xD;
      differentiate into cartilage-producing cells - chondrocytes. The acquisition of MSC does not&#xD;
      require invasive surgical intervention or cartilage extraction from other sites as required&#xD;
      by other cell-based strategies. The investigators inject allogeneic human mesenchymal stem&#xD;
      cells to the cartilage lesions in patients via intra-articular injection method, and to&#xD;
      investigate the efficacy and safety.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis is one of the commonest diseases in the world, with a global disease burden of&#xD;
      83%. Plain radiograph remained the main modality in diagnosing osteoarthritis. Chondrogen is&#xD;
      a mesenchymal stem cell-derived from umbilical cord tissue product. The mesenchymal stem cell&#xD;
      is used for the study because of its ability to proliferate and differentiate into various&#xD;
      tissues such as chondrocytes, adipocytes, and osteocytes. Various clinical studies have been&#xD;
      conducted for arthritis, orthopedic, joint, and cartilage.&#xD;
&#xD;
      This study will enroll 100 patients age 30-70 years old. They will be divided into 2 groups&#xD;
      which are the group which will receive the investigational drug (ChondrogenTM and HA) and&#xD;
      another group will receive a placebo (saline and HA). It will be a randomized double-blinded&#xD;
      study where the participants and the investigator would not know what are the things being&#xD;
      received. This study will be conducted for 24 months. The injection will be given on the&#xD;
      baseline day after screening the volunteers. The patients will be assessed on VAS, WOMAC,&#xD;
      IKDC, KOOS PROMIS29, the interleukins, and MRI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>100 patients will be selected from 2 different study sites. Each study site comprises 50 patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The outcomes assessor will help to screen the participants and send them to the clinical investigators for further medical screening. The participant's personal details will be private and confidential to the outcomes assessor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>VAS score</measure>
    <time_frame>12 months</time_frame>
    <description>Change from Baseline in Visual Analogue Scale (VAS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC score</measure>
    <time_frame>12 months</time_frame>
    <description>Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Score (WOMAC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IKDC score</measure>
    <time_frame>12 months</time_frame>
    <description>Change from Baseline in knee function change and improvement (IKDC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>KOOS score</measure>
    <time_frame>12 months</time_frame>
    <description>Change from Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PROMIS29 score</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Patient-Reported Outcomes Measurement Information System (PROMIS29) scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellegren-Lawrence grading</measure>
    <time_frame>12 months</time_frame>
    <description>Number of participants evaluated by X-ray and MRI of knee OA from baseline Kellegren-Lawrence grading system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukins</measure>
    <time_frame>12 months</time_frame>
    <description>Changes of interleukins (IL-1b, IL-6, PGE-2, TGF-b, TNF-a, IGF-1) of articular cavity fluid from baseline to week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Active Participant of Phase 2B Clinical Study Chondrogen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 participants will receive the investigational drug (Chondrogen and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Participant of Phase 2B Clinical Study Chondrogen</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 participants will receive the placebo (Saline and Hyaluronic Acid) through the intra-articular injection method. The participants will receive the investigational drug one time. The injection will be provided to the participant on the baseline day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Chondrogen</intervention_name>
    <description>Mesenchymal stem cell-derived from umbilical cord Wharton Jelly and hyaluronic acid</description>
    <arm_group_label>Active Participant of Phase 2B Clinical Study Chondrogen</arm_group_label>
    <other_name>Mesenchymal Stem Cell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Consist of saline and hyaluronic acid</description>
    <arm_group_label>Placebo Participant of Phase 2B Clinical Study Chondrogen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  30-70 years old&#xD;
&#xD;
          -  No serious infection, chronic diseases, diabetes and tuberculosis&#xD;
&#xD;
          -  Idiopathic or secondary osteoarthritis of the knee with grade 1-3 defined by the&#xD;
             modified Kellgren-lawrence classification&#xD;
&#xD;
          -  Written informed consents were obtained from all subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Women of childbearing potential unwilling to use two forms of contraception&#xD;
&#xD;
          -  Cognitively impaired adults&#xD;
&#xD;
          -  Presence of large meniscal tears&#xD;
&#xD;
          -  Inflammatory or post-infectious arthritis&#xD;
&#xD;
          -  More than 5 degrees of varus or valgus deformity&#xD;
&#xD;
          -  Kellgren Lawrence grade 4 osteoarthritis in two compartments in persons over 60 years&#xD;
             of age&#xD;
&#xD;
          -  Intra-articular corticosteroid injection within the 3 previous months&#xD;
&#xD;
          -  Major neurologic deficit&#xD;
&#xD;
          -  Arthroscopy during the previous 6 months&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus&#xD;
&#xD;
          -  Immunosuppressive or anticoagulant treatment&#xD;
&#xD;
          -  NSAID therapy within 15 days prior to inclusion in the study&#xD;
&#xD;
          -  Serious medical illness with a life expectancy of less than 1 year&#xD;
&#xD;
          -  Prior admission for substance abuse&#xD;
&#xD;
          -  Body Mass Index (BMI) of 40 kg/m2 or greater&#xD;
&#xD;
          -  Patient receiving experimental medication or participating in another clinical study&#xD;
             within 30 days of signing the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Badrul Akmal Hisham, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPUKM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prakash Nathan, MBA</last_name>
    <phone>03-88902968</phone>
    <email>research@meluhalifesciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raisah Hadi, MSC</last_name>
    <phone>03-88902968</phone>
    <phone_ext>105</phone_ext>
    <email>research@meluhalifesciences.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Orthopedic &amp; Traumatology, Faculty of Medicine, Hospital Canselor Tuanku Mukhriz, UKM Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, 56000 Kuala Lumpur.</name>
      <address>
        <city>Cheras</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Badrul Akmal Hisham Md. Yusoff, MBBS</last_name>
      <phone>012-5196119</phone>
      <email>badrul.akmal.hisham.md.yusof@ppukm.ukm.edu.my</email>
    </contact>
    <investigator>
      <last_name>Badrul Akmal Hisham Md. Yusoff, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

